Could an Ancient Drug Help Fight Severe COVID-19?

WEDNESDAY, April 22, 2020 -- As researchers hunt for ways to treat severe COVID-19 infections, a new trial will ask whether an old arthritis drug can prevent serious complications in the first place. The medication, called colchicine, is an oral...
Source: - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

ConclusionsNo antirheumatic drug intake was associated with an increased or decreased risk of developing COVID-19 infection in our cohort of patients suffering from immune-mediated inflammatory diseases.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
Endocr Regul. 2021 Sep 13;55(3):174-181. doi: 10.2478/enr-2021-0019.ABSTRACTThe pathophysiology of COVID comprises an exaggerated pro-inflammatory response. Hypothalamic-pituitary-adrenal (HPA) axis has a crucial role in various inflammatory conditions and modulated immunological response. Limited evidence is available regarding the incidence and the effect of HPA dysfunction in COVID-19. Although the cortisol levels have only been estimated in a few studies, the dehydroepiandrosterone sulfate (DHEAS) release from the adrenal gland has not been explored yet. In this mini review, the authors discuss the role of dehydroepian...
Source: Endocrine Regulations - Category: Endocrinology Authors: Source Type: research
ObjectiveTo assess in rheumatoid arthritis (RA) patients, treated with different immunosuppressive therapies, the induction of SARS-CoV-2-specific immune response after vaccination in terms of anti-region-binding-domain (RBD)-antibody- and T-cell-specific responses against spike, and the vaccine safety in terms of clinical impact on disease activity.MethodsHealth care workers (HCWs) and RA patients, having completed the BNT162b2-mRNA vaccination in the last 2 weeks, were enrolled. Serological response was evaluated by quantifying anti-RBD antibodies, while the cell-mediated response was evaluated by a whole-blood test quan...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractManaging patients with rheumatic disease during the COVID-19 pandemic has posed a unique challenge. Immunosuppressed patients are at an increased risk for developing severe COVID-19 and may not derive full protection from the vaccine (1-5). Thus, it is paramount we develop strategies whereby rheumatic disease patients can be protected from the pandemic virus and its variants.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: LETTER TO THE EDITOR Source Type: research
AbstractThe aim of this study was to investigate the effects of lockdown on the mental health (anxiety and depression) and quality of life (QOL) of people with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in the context of the COVID-19 pandemic and public health measures instituted at a national level by the New Zealand Government. The present cohort was 104 individuals with RA (73.1%) and AS (26.9%) who had previously completed surveys for the Patient Opinion Real-Time Anonymous Liaison (PORTAL) project in 2018. Participants completed an online survey between July and September 2020 assessing their experience...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Hospitalized COVID-19 patients died less often if they received Eli Lilly's rheumatoid arthritis drug baricitinib along with the other treatments their doctors had prescribed, according to a study published in The Lancet Respiratory Medicine.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
AbstractPatients with rheumatic and musculoskeletal diseases (RMDs) on immunosuppressants are considered a vulnerable group in COVID-19 pandemic and vaccination is the mainstay for the prevention of this infection (1). To date, recommendations and data for COVID-19 vaccination in adolescent patients with RMDs are lacking (2). International societies and post-authorization safety reports of the novel mRNA COVID-19 vaccines are generally reassuring; nonetheless their safely profile in adolescents with RMDs on immune-modulating treatment is unknown, since these individuals were excluded from the vaccine trials (3-5).
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: LETTER TO THE EDITOR Source Type: research
ConclusionSerum biomarker profiles clearly separate COVID-19 from MAS or secondary HLH in terms of distinguishing the severe systemic hyperinflammation that occurs following SARS –CoV-2 infection. These findings could be useful in determining the efficacy of drugs targeting key molecules and pathways specifically associated with systemic cytokine storm conditions in the treatment of COVID-19.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Brief Report Source Type: research
Purpose of review Janus Kinase (JAK) inhibitors have been successfully utilized in the clinical treatment of several rheumatologic (e.g. rheumatoid arthritis) and inflammatory diseases (e.g. hemophagocytic lymphohistiocytosis). Based on the growing evidence that moderate and severe COVID-19 infections are associated with a dysregulated inflammatory state, this class of medications has been repurposed as a potential therapy for COVID-19, an infection caused by Severe Acute Respiratory Syndrome Coronavirus 2. Recent findings Three JAK inhibitors have been evaluated in human studies of COVID-19: Baricitinib, Tofaci...
Source: Current Opinion in Critical Care - Category: Nursing Tags: SEVERE INFECTIONS: Edited by Andre C. Kalil Source Type: research
CONCLUSION: The higher prevalence of Covid-19 in ASD patients along with the significant correlations with important clinical features and therapeutic regimens suggests the need to develop targeted prevention/management strategies during the current pandemic wave.PMID:34477509 | DOI:10.2174/1381612827666210903103935
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Arthritis | Colchicine | Colcrys | COVID-19 | General Medicine | Rheumatology